Rare cancers account for ~25–30% of all cancer diagnoses and 25% of cancer deaths, representing a substantial burden of disease. However, basic science research, clinical trials and approval of new therapies for rare cancers are lacking. This translates into a worse prognosis for patients with a rare cancer than for those with common cancers. With the number of rare cancers increasing, finding more appropriate solutions for diagnosing, managing and studying rare cancers is essential.
We are thrilled to welcome Lisa as a postdoctoral researcher. Lisa recently obtained her PhD ...
Nicolas Alcala received a mentored award from the Neuroendocrine tumor research foundation (NETRF), with Lynnette ...
Emilie Mathian has successfully defended her PhD thesis after three years of hard work within ...
Rare Cancer Genomics
NETRF 2022
RCG Initiative 2020